Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Ziconotide

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 5,605,130Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ESTEVE to Acquire TerSera Infusion Therapies Unit in U.S.
    ESTEVE to Acquire TerSera Infusion Therapies Unit in U.S.

    13 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260113327900/en/ESTEVE-to-Acquire-TerSera-Therapeutics-Infusion-Specialty-Therapies-Business-Unit-Expanding-U.S.-Presence

    BUSINESSWIRE
    13 Jan 2026
    Share Share
    TerSera to Present Real-World PRIALT Data at ASPN 2025
    TerSera to Present Real-World PRIALT Data at ASPN 2025

    18 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250718506823/en/TerSera-Therapeutics-to-Present-Real-World-Data-on-Intrathecal-Ziconotide-PRIALT-Prescription-Patterns-at-ASPN-2025

    BUSINESSWIRE
    18 Jul 2025
    Share Share
    Tersera Notes PACC Guidelines Update For PRIALT Administration
    Tersera Notes PACC Guidelines Update For PRIALT Administration

    23 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240723453532/en

    BUSINESSWIRE
    23 Jul 2024
    Share Share
    AmbioPharm Inc. Working with University of California Davis to Develop Non-Opioid Peptide-Based Pain Therapeutics
    AmbioPharm Inc. Working with University of California Davis to Develop Non-Opioid Peptide-Based Pain Therapeutics

    20 Jul 2021

    // PRESS RELEASE

    https://www.ambiopharm.com/news-press/ambiopharm-inc-working-with-university-of-california-davis-to-develop-non-opioid-peptide-based-pain-therapeutics/

    PRESS RELEASE
    20 Jul 2021
    Share Share
    Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics for Prialt
    Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics for Prialt

    29 Jun 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-enters-into-agreement-with-tersera-therapeutics-llc-for-prialt-300674775.html

    PR NEWSWIRE
    29 Jun 2018
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.